Who is sponsoring NCT02436226?

NCT02436226 is sponsored by Mohamed Sayed Abdelhafez.

What condition does NCT02436226 study?

NCT02436226 studies Infertility, Polycystic Ovarian Syndrome.

Is NCT02436226 still recruiting?

NCT02436226 is currently completed. Last updated 27 October 2023.

Last reviewed 2023-10-27 · How we verify

NCT02436226

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Use of Low Dose of Human Chorionic Gonadotropin During Ovulation Induction With Clomiphene Citrate in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome

Completed Phase 4 Last updated 27 October 2023

What this trial tests

Phase 4 trial testing Clomiphene citrate and Human chorionic gonadotropin (HCG) in Infertility in 300 participants. Completed in 1 January 2023.

Timeline

1 March 2016

Primary endpoint
1 January 2023

1 January 2023

Quick facts

Lead sponsor	Mohamed Sayed Abdelhafez
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	300
Start date	1 March 2016
Primary completion	1 January 2023
Estimated completion	1 January 2023
Sites	1 location across Egypt

Drugs / interventions tested

Clomiphene citrate and Human chorionic gonadotropin (HCG) — full drug profile →
Clomiphene citrate — full drug profile →

Conditions studied

Infertility — all drugs for Infertility →
Polycystic Ovarian Syndrome — all drugs for Polycystic Ovarian Syndrome →

Sponsor

Mohamed Sayed Abdelhafez — full company profile →

Who can join

Adults 20 to 35, female only, with Infertility or Polycystic Ovarian Syndrome. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Ovulation rate
Time frame: 3 months
Number of ovulatory cycles divided by the number of stimulation cycles

Sponsor's own description

The purpose of this study is to evaluate the effect of administration of low dose of human chorionic gonadotropin (HCG) after use of clomiphene citrate (CC) for induction of ovulation in infertile women having CC resistant polycystic ovarian syndrome (PCOS).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Network-based stage-specific drug repurposing for Alzheimer's disease.
Savva K, Zachariou M, Bourdakou MM, Dietis N, et al · · 2022 · cited 24× · PMID 35386099 · DOI 10.1016/j.csbj.2022.03.013
Competence of Combined Low Dose of Human Chorionic Gonadotropin (HCG) and Clomiphene Citrate (CC) Versus Continued CC during Ovulation Induction in Women with CC-Resistant Polycystic Ovarian Syndrome: A Randomized Controlled Trial.
Thabet M, Abdelhafez MS, Elshamy MR, Albahlol IA, et al · · 2024 · cited 3× · PMID 39202581 · DOI 10.3390/medicina60081300

Verify or expand the search:

Other recruiting trials for Infertility

Currently open trials in the same condition.

NCT07074015 — IntelliWell: An AI-Assisted Imaging Platform for Detection and Location of Ultra-Rare Testicular Sperm in Surgical Speci · NA · recruiting
NCT07358468 — Impact Of FET Preparation Protocol On Endometrial Peristalsis: A Prospective Cohort Study · recruiting
NCT07340827 — A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH · Phase 3 · recruiting
NCT07369362 — To Investigate if the Harvester® Improves Sperm Motility and Blastocyst Utilization (the Percent of Fertilized Eggs That · NA · active not recruiting
NCT07153367 — Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauter · Phase 2 · recruiting

Other Mohamed Sayed Abdelhafez trials

Trials by the same sponsor.

NCT02699437 — Prevalence of Antiphospholipid Antibodies Among Women With Preeclampsia · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02436226 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mohamed Sayed Abdelhafez
Last refreshed: 27 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02436226.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing